Krishna Institute of Medical Sciences Ltd

BSE : 221645 NSE : KIMS ISIN : INE967H01017 Industry : Hospital & Healthcare Services
1,946.25
Change: -9.15 (-0.47 %)
As on 01-Dec-2023 12:00 AM
Prev.Close 1,955.40
Open 1,973.00
Day's High 1,986.95
Day's Low 1,938.90
Mkt.Cap ( Cr.) 15,575.45
Face Value 10.00
PE Ratio 45.73
PB Ratio 6.90

52 Week High Low

Low: 1,282.00
High: 2,229.90
LTP:1,946.25

Lifetime High Low

Low: 937.55
High: 2,229.90
LTP:1,946.25

Krishna Institute of Medical Sciences Ltd

BSE : 221645 NSE : KIMS ISIN : INE967H01017 Industry : Hospital & Healthcare Services
1,946.45
B S Sip
Change: -8.25 (-0.42 %)
As on 01-Dec-2023 12:00 AM
Prev.Close 1,954.70
Open 1,988.95
Day High 1,988.95
Day Low 1,942.35
Mkt.Cap ( Cr. ) 15,577.05
Face Value 10.00
P/E Ratio 45.73
PB Ratio 6.90

52 Week High Low

Low:1,283.95
High:2,225.30
LTP:1,946.45

Lifetime High Low

Low:938.05
High:2,225.30
LTP:1,946.45

P/E Ratio

52 W L(14.96)
52 W H(40.26)

P/E Ratio

52 W L(14.96)
52 W H(40.26)
Had I Invested a sum of 1,00,000 on the same day 5 years ago,the money would have become 195220.42 ( a of 14.32 p.a.)

Key Levels

Support Level 1 1,922.17
Support Level 2 1,888.93
Resistance Level 1 1,988.82
Resistance Level 2 2,022.23

Moving Average

20 Days --
50 Days --
100 Days --
200 Days --
Vaidya Sane Ayurved Laboratories Ltd. 249.00 Change: 19.65 (8.57%)
PE : 49.89
1Y Return: 79.46%

B S
Aatmaj Healthcare Ltd. 43.90 Change: 2.90 (7.07%)
PE : 15.69
1Y Return: 0.00%

B S
Aster DM Healthcare Ltd. 401.25 Change: 18.85 (4.93%)
PE : 67.09
1Y Return: 69.59%

B S
Lotus Eye Hospital And Institute Ltd. 88.65 Change: 3.85 (4.54%)
PE : 43.77
1Y Return: 2.37%

B S
FY 2023FY 2022FY 2021FY 2020FY 2019
EBDITA Margin (%)34.2237.1634.0126.958.99
PBT Margin (%)29.8032.4527.2618.55-1.90
PAT Margin (%)22.3024.3520.2315.33-6.18
ROCE (%)22.5831.2429.5722.723.90
ROE (%)16.7924.3724.6421.48-28.67
FY 2023FY 2022FY 2021FY 2020FY 2019
Total Income ( Cr.)1,156.311,170.34942.30797.06713.39
Gross Profit ( Cr.)382.63415.93298.86189.1727.55
Profit Before Tax ( Cr.)337.33371.00254.26146.51-13.42
Tax ( Cr.)84.8492.6465.6125.4030.23
Profit After Tax ( Cr.)252.49278.37188.65121.11-43.66
NAME DESIGNATION
Umashankar Mantha Company Secretary & Compliance Officer
Bhaskara Rao Bollineni Chairman & Managing Director
Anitha Dandamudi Whole Time Director
Rajeswara Rao Gandu Non Executive Independent Director
Saumen Chakraborty Non Executive Independent Director
Pankaj Vaish Non Executive Independent Director
Venkata Ramudu Jasthi Non Executive Independent Director
Abhinay Bollineni Executive Director & Chief Executive Officer
Y Prameela Rani Non Executive Independent Director
Shantanu Rastogi Non Executive Director
Ratna Kishore Kaza Non Executive Independent Director
Ilaa J Udeshi Company Secretary & Compliance Officer
Krishna Inst.Medi reports Profit after tax of Rs 661.59 Mln, in the September 2023 quarter
Type: CORPORATE RESULT
Date: 07-Nov-2023 05:21 PM
--
Krishna Institute of Medical rises on acquiring additional stake in SPANV Medisearch Lifesciences
Type: MOVERS TODAY
Date: 01-Nov-2023 09:33 AM
Consequently, the company now holds 62.44% of the total paid-up Equity Share capital of M/s SPANV Medisearch Lifesciences
Krishna Institute of Medical Sciences’ arm acquires additional stake in Kondapur Healthcare
Type: NEWS
Date: 23-Oct-2023 05:37 PM
Accordingly, the total equity stake of the Material Subsidiary of the company in the Target Entity as of October 23, 2023, is 37.18%
Krishna Institute of Medical Sciences gains as its arm acquires additional stake in M/s. Kondapur Healthcare
Type: MOVERS TODAY
Date: 18-Sep-2023 10:23 AM
Accordingly, the total equity stake of the Material Subsidiary of the company in the Target Entity as of September 16, 2023, is 28.79%
Krishna Institute of Medical Sciences’ arm acquires 11.52% stake in M/s. Kondapur Healthcare
Type: NEWS
Date: 18-Sep-2023 09:59 AM
The total cost of acquisition is Rs 20 crore
Krishna Institute of Medical Sciences’ arm acquires additional stake in Kondapur Healthcare
Type: NEWS
Date: 16-Sep-2023 05:37 PM
Accordingly, the total equity stake of the Material Subsidiary of the company in the Target Entity as of September 16, 2023, is 28.79%